secwatch.observer — SEC 8-K summary
======================================

Issuer:     INVO Fertility, Inc. (IVF)
CIK:        0001417926
Form:       8-K/A
Filed at:   2024-12-12T23:59:59+00:00
Accession:  0001493152-24-049815
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NAYA Biosciences completes merger with Legacy NAYA; stock and debt exchange detailed
--------------------------------------------------------------------------------

- Each Legacy NAYA share exchanged for 118,148 NAYA common shares and 30,375 Series C-1 Preferred shares (convertible only after stockholder approval).
- $8.58M Legacy NAYA debt converted into 669,508 common shares and 8,576 Series C-2 Preferred; remaining $3.93M exchanged for new 7% Senior Secured Convertible Debenture due Dec 2025.
- Dr. Daniel Teper appointed President; CEO Steven Shum and CFO Andrea Goren remain; Teper and Lyn Falconio join board of directors.
- Legacy NAYA audited results: no revenue for 2022 or 2023; net loss $3.28M in 2023, $9.5M in 2022; going concern noted.
- Stockholder meeting required to ratify merger, increase authorized shares to 100M, and approve reverse stock split (1:2 to 1:20).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1417926/000149315224049815/0001493152-24-049815-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1417926/000149315224049815/form8-ka.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-049815

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer